Literature DB >> 15345212

Treatment of Autoimmune Hepatitis: Current and Future Therapies.

Fernando Alvarez1.   

Abstract

Autoimmune hepatitis is an uncommon liver disease affecting children and adults. Early diagnosis and start of treatment improve the response and long-term outcome. Initial treatment depends on patient's age and the clinical, laboratory, and histological features that allow the prediction of the response, as well as the presence or absence of associated extrahepatic disorders. In specialized centers, short-term cyclosporine is used safely and successfully to control the liver inflammatory process. Low doses of prednisone in association with azathioprine are sufficient to sustain the response. Maintenance treatment must be administered for several years, and withdrawal can be attempted after at least 4 years of a complete and sustained response. Future research should focus on the recovery of immune homeostasis in these patients by less aggressive means.

Entities:  

Year:  2004        PMID: 15345212     DOI: 10.1007/s11938-004-0054-9

Source DB:  PubMed          Journal:  Curr Treat Options Gastroenterol        ISSN: 1092-8472


  46 in total

1.  Azathioprine-induced lung toxicity and efficacy of cyclosporin A in a young girl with type 2 autoimmune hepatitis.

Authors:  F Perreaux; D Zenaty; F Capron; P Trioche; M Odièvre; P Labrune
Journal:  J Pediatr Gastroenterol Nutr       Date:  2000-08       Impact factor: 2.839

Review 2.  The clinical pharmacology of 6-mercaptopurine.

Authors:  L Lennard
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

Review 3.  Developing a new generation of TNFalpha antagonists for the treatment of rheumatoid arthritis.

Authors:  Roy Fleischmann; Dave Shealy
Journal:  Mol Interv       Date:  2003-09

4.  Subfulminant hepatic failure in autoimmune hepatitis type 1: an unusual form of presentation.

Authors:  D Herzog; A M Rasquin-Weber; D Debray; F Alvarez
Journal:  J Hepatol       Date:  1997-09       Impact factor: 25.083

5.  International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis.

Authors:  F Alvarez; P A Berg; F B Bianchi; L Bianchi; A K Burroughs; E L Cancado; R W Chapman; W G Cooksley; A J Czaja; V J Desmet; P T Donaldson; A L Eddleston; L Fainboim; J Heathcote; J C Homberg; J H Hoofnagle; S Kakumu; E L Krawitt; I R Mackay; R N MacSween; W C Maddrey; M P Manns; I G McFarlane; K H Meyer zum Büschenfelde; M Zeniya
Journal:  J Hepatol       Date:  1999-11       Impact factor: 25.083

6.  The successful treatment of autoimmune hepatitis with 6-mercaptopurine after failure with azathioprine.

Authors:  D S Pratt; D P Flavin; M M Kaplan
Journal:  Gastroenterology       Date:  1996-01       Impact factor: 22.682

7.  Milk could decrease the bioavailability of 6-mercaptopurine.

Authors:  G E Rivard; K T Lin; J M Leclerc; M David
Journal:  Am J Pediatr Hematol Oncol       Date:  1989

8.  Study of antigenic sites on the asialoglycoprotein receptor recognized by autoantibodies.

Authors:  O Hajoui; S Martin; F Alvarez
Journal:  Clin Exp Immunol       Date:  1998-09       Impact factor: 4.330

9.  Linkage disequilibrium between HLA class II region and autoimmune hepatitis in pediatric patients.

Authors:  Idriss Djilali-Saiah; Reginald Renous; Sophie Caillat-Zucman; Dominique Debray; Fernando Alvarez
Journal:  J Hepatol       Date:  2004-06       Impact factor: 25.083

10.  Prognosis of histological cirrhosis in type 1 autoimmune hepatitis.

Authors:  S K Roberts; T M Therneau; A J Czaja
Journal:  Gastroenterology       Date:  1996-03       Impact factor: 22.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.